| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8661010 | Hellenic Journal of Cardiology | 2016 | 11 Pages |
Abstract
In this review, we present the results of recent clinical trials on type 2 diabetes mellitus medications and outline what can be anticipated from ongoing clinical trials.
Keywords
A1cEMPA-REG OUTCOMESGLT2iCarolinaFDATECOSSodium glucose co-transporter 2 inhibitorN-Terminal pro Brain Natriuretic PeptideHFHDPP-4iMACETZDU.S. Food & Drug AdministrationNT-proBNPEGFRT2DMGLP-1ACSEMAAHAARBNNTAngiotensin converting enzyme inhibitorEuropean Medicines agencystandard of careAmerican Heart AssociationCardiovascular safetyHeart failure hospitalizationcardiovascular diseasechronic kidney diseasethiazolidinedionesmajor adverse cardiac eventsAntidiabetic drugsType 2 diabetes mellitusCVDrecordAcute coronary syndromeSOCnumber needed to treatconfidence intervalcardiovascularCANVASAngiotensin receptor blockersEXAMINEACEI یا angiotensin convert enzyme inhibitorestimated glomerular filtration rateheart failureCKDhazard ratioglucagon-like peptide-1Proactive
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Nikitas P. Skliros, Charalambos Vlachopoulos, Dimitrios Tousoulis,